[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Temps et al., 2021 - Google Patents

A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability

Temps et al., 2021

View HTML
Document ID
1582875264109413658
Author
Temps C
Lietha D
Webb E
Li X
Dawson J
Muir M
Macleod K
Valero T
Munro A
Contreras-Montoya R
Luque-Ortega J
Fraser C
Beetham H
Schoenherr C
Lopalco M
Arends M
Frame M
Qian B
Brunton V
Carragher N
Unciti-Broceta A
Publication year
Publication venue
Cancer research

External Links

Snippet

Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes …
Continue reading at aacrjournals.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Temps et al. A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability
Hatlen et al. Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma
Nebenfuehr et al. The role of CDK6 in cancer
Saha et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma
Karoulia et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling
Blake et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Isakoff et al. Breast cancer–associated PIK3CA mutations are oncogenic in mammary epithelial cells
Cheung et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors
Caretti et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas
Sandhöfer et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Bax et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines
Ferguson et al. Profiles of brain metastases: prioritization of therapeutic targets
Adams et al. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer
Xu et al. AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B
Beadnell et al. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
Luchman et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival
Suwaki et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma
Troutman et al. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1
Serra et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance
Saturno et al. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
Keegan et al. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia
Ku et al. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models
Luo et al. Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition
Ramroop et al. Impact of phosphoproteomics in the era of precision medicine for prostate cancer
Chougule et al. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia